SQNMF (Sequana Medical NV) EBIT: $-43.20 Mil (TTM As of Jun. 2025)

What is Sequana Medical NV EBIT?

Sequana Medical NV SQNMF 29 EBIT is $-43.20 Mil as of Jun. 2025. GuruFocus rates SQNMF with a GF Score™ of 29/100 and a GF Value™ of $0.48. The stock has 12 warning signs investors should review.

Sequana Medical NV's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was $-6.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $-43.20 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sequana Medical NV's annualized ROC % for the quarter that ended in Jun. 2025 was -33.79%. Sequana Medical NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -620.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sequana Medical NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -46.45%.

Sequana Medical NV (OTCPK:SQNMF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sequana Medical NV's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-19.798 * ( 1 - 0% )	/	( (55.661	+	61.526)	/ 2 )
=	-19.798	/	58.5935
=	-33.79 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.413	-	3.751	-	( 3.986	-	max(0, 55.718	-	6.719	+	3.986	))
=	55.661

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16.806	-	3.235	-	( 8.436	-	max(0, 60.157	-	12.202	+	8.436	))
=	61.526

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sequana Medical NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.434	/	( ( (1.858 + max(-11.673, 0))	+	(2.152 + max(-9.832, 0)) )	/	2 )
=	-12.434	/	( ( 1.858	+	2.152 )	/	2 )
=	-12.434	/	2.005
=	-620.15 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	2.142	+	0.276)	-	(3.751	+	0	+	10.34)
=	-11.673

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	2.825	+	0.583)	-	(3.235	+	0	+	10.005)
=	-9.832

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sequana Medical NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2025 )
	=	-43.196	/	92.992
	=	-46.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV EBIT Related Terms

Sequana Medical NV EBIT Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's EBIT can be seen below:

Sequana Medical NV EBIT Chart

Sequana Medical NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-21.75

-25.61

-31.25

-32.83

-43.70

Sequana Medical NV Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
EBIT	Get a 7-Day Free Trial														-15.28	-17.46	-6.91	-36.98	-6.22

SQNMF vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Sequana Medical NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequana Medical NV EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sequana Medical NV's EV-to-EBIT falls into.

Save Embed

29GF Score

Sequana Medical NV SQNMF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sequana Medical NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-43.20 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-43.20 Mil mean?

Sequana Medical NV (SQNMF) has a EBIT of $-43.20 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sequana Medical NV.

Is Sequana Medical NV's EBIT too high?

Sequana Medical NV's current EBIT is $-43.20 Mil. Overall, Sequana Medical NV has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does Sequana Medical NV's EBIT compare to ABT and SYK?

Sequana Medical NV's EBIT of $-43.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sequana Medical NV. Sequana Medical NV's current EBIT is $-43.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sequana Medical NV stock overvalued right now?

Sequana Medical NV (SQNMF) has a current EBIT of $-43.20 Mil. The stock's GF Value™ is $0.48, compared to a current price of $1.22 — trading 154.2% above its estimated fair value. The current EBIT is $-43.20 Mil. Sequana Medical NV's overall GF Score™ is 29/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Sequana Medical NV (SQNMF), the current EBIT is $-43.20 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (SQNMF) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of $1.22 is trading 154.2% above its estimated GF Value™ of $0.48.

Key valuation signals for SQNMF:

EBIT: $-43.20 Mil
GF Value™: $0.48 vs. price of $1.22 (154.2% above fair value)
GF Score™: 29/100 with 12 warning signs

No single metric tells the full story. See the SQNMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XBRU:NYXH ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA STE ZBH XSWX:SOON SHSE:688271 LSE:SN.PEN TSE:7733 GMED PODD

Other Exchanges 2SE:Germany SEQUA:Belgium

Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051

Website https://www.sequanamedical.com

Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

29GF Score

Get the complete analysis for SQNMF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22

Price

$0.48

GF Value

View SQNMF Analysis

See EBIT data for all stocks →